Efficacy and safety of neoadjuvant pertuzumab, trastuzumab and chemotherapy in non-metastatic HER2-positive breast cancer in the Asian population: a multicentre analysis

Background: Pertuzumab combined with trastuzumab and chemotherapy is now the standard neoadjuvant treatment for non-metastatic HER2-positive early breast cancer (HER2+ BC). However, information on the efficacy of this combination in Asian population is sparse. This retrospective study aims to assess the clinical outcome of adding pertuzumab to trastuzumab and chemotherapy (PH/CTX) for stage II to III HER2+ BC in an Asian cohort.

Source: European Journal of Cancer - September 30, 2020 Category: Cancer & Oncology Authors: W.L.W. Chan, C. Kwok, I. Soong, W.S.K. Li, W. Tin, W. Soo, T.Y. Ng, H.C.W. Choi, M.Y. Luk, N.Kai Cheong Roger Tags: POSTERS B: Systemic Treatment Source Type: research